半数以上的人在服用靶向抗癌药物伊布替尼（ibrutinib）后6个月内出现新的或恶化的高血压。这项分析也是第一次将伊布替尼相关高血压与心脏问题特别是房颤（atrial fibrillation）的高风险联系起来。此外，无论规定的剂量如何，伊布替尼与心血管并发症的关系仍然存在。

Ibrutinib linked to high blood pressure and other heart problems, study suggests

https://www.sciencedaily.com/releases/2019/10/191003141548.htm

Journal Reference:

1. Tyler Dickerson, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Kyle Porter, Devin Haddad, Avirup Guha, Kerry A. Rogers, Seema Bhatt, John C. Byrd, Jennifer A. Woyach, Farrukh Awan, Daniel Addison. Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation. Blood, 2019; blood.2019000840 DOI: 10.1182/blood.2019000840